SecBot SecBot
8-K ·Filed May 6, 2026

PCVX

Vaxcyte, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001649094-26-000015
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The earnings miss is largely discounted by the market given the pre-revenue stage. Focus is on the upcoming OPUS-1 topline readout in Q4 2026, which is the key catalyst. Monitor stock price volatility around Phase 3 data expectations and any regulatory updates.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$51.48
T+0 close · May 6, 2026 · via day close
Latest settled
+3.98%
T+60 · $53.53
Vs SPY
+0.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $51.48entry
  2. T+1 · 6mo ago +2.97%α +2.14% · $53.01
  3. T+5 · 6mo ago +5.38%α +3.88% · $54.25
  4. T+20 · 6mo ago −8.84%α −11.97% · $46.93
  5. T+60 · 4mo ago +3.98%α +0.15% · $53.53

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxcyte reported Q1 2026 net loss of $320.6M (-$2.30 per share), significantly worse than the consensus estimate of -$1.86 and more than double the prior year's loss of $140.7M. R&D expenses surged to $312.8M as Phase 3 trials enrolled fully. The earnings miss is overshadowed by pipeline progress, with all three OPUS Phase 3 trials now fully enrolled and OPUS-1 topline data expected in Q4 2026.

Key Financial Metrics

EPS
−$2.30
est −$1.86 · -23.7%
Revenue
$0.00
Rating
strong miss

Key Facts

  • Net loss per share Q1 2026: -$2.30 vs consensus -$1.86 (23.7% miss)
  • Net loss widened to $320.6M from $140.7M YoY
  • R&D expenses increased to $312.8M from $148.1M YoY
  • Cash, cash equivalents and investments: $2.74B as of March 31, 2026 (up from $2.44B in December 2025, including $601.8M net from Feb equity offering)
  • Enrollment completed for all three OPUS Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) with 6,191 adults dosed
  • VAX-31 Phase 1/2 adult data published in The Lancet Infectious Diseases
  • VAX-31 infant Phase 2 study fully enrolled; infant data expected by end of first half 2027

Financial Impact

EPS miss of $0.44 per share vs consensus, representing a 23.7% negative surprise

epsnetLossrAndDExpenses

Risk Factors

  • OPUS-1 Phase 3 data may fail to meet noninferiority or superiority endpoints
  • Cash burn rate is accelerating; additional equity dilutive financing may be needed before commercialization
  • Regulatory or manufacturing delays could push BLA submission beyond current timeline

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001649094-26-000015
Document: pcvx-20260506.htm0001649094-26-000015
Document: 0001649094-26-000015-index-headers.html0001649094-26-000015
Document: 0001649094-26-000015-index.html0001649094-26-000015
Document: 0001649094-26-000015.txt0001649094-26-000015
8-K Data (Synthetic)0001649094-26-000015

US Market Status

Market Closed · Opens Wed (12h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026